Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DiagnoCure, Inc.
DiagnoCure wins U.S. patent for PCA3
April 8th, 2006
DiagnoCure, Inc., (CUR), a developer and provider of cell-based assays and molecular diagnostics for early detection of cancer, has confirmed exclusive rights to PCA3, its highly prostate-cancer specific gene. In a notice posted March 7, 2006, to its official website, the United States Patent & Trademark Office (USPTO) indicated it has granted a patent on the PCA3 gene technology, which encompasses both therapeutic and diagnostic applications. The U.S. patent 7,008,765 "PCA3, PCA3 genes, and methods of use" is at the forefront of several families of patent applications covering PCA3, its structure, and its role in the diagnosis, prognosis, and therapeutics of prostate...
Source: Law & Health Weekly (2006-04-08)
|
